BBOT
Bridgebio Oncology Therapeut
NASDAQ · Biotechnology
$10.70
+0.55 (+5.42%)
Open$10.50
Previous Close$10.15
Day High$11.55
Day Low$10.22
52W High$14.87
52W Low$8.70
Volume—
Avg Volume260.2K
Market Cap855.88M
P/E Ratio181.43
EPS$0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+302.8% upside
Current
$10.70
$10.70
Target
$43.10
$43.10
$22.76
$43.10 avg
$48.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 230.06M | 225.69M | 230.96M |
| Net Income | 46.84M | 61.14M | 59.73M |
| Profit Margin | 20.4% | 27.1% | 25.9% |
| EBITDA | 108.29M | 111.55M | 110.87M |
| Free Cash Flow | 56.78M | 36.61M | 55.99M |
| Rev Growth | -2.3% | +22.3% | +7.3% |
| Debt/Equity | 0.31 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |